Nanobodies raised against monomeric alpha-synuclein inhibit fibril formation and destabilize toxic oligomeric species

Cited 55 time in webofscience Cited 0 time in scopus
  • Hit : 73
  • Download : 0
Background: The aggregation of the protein alpha-synuclein (alpha S) underlies a range of increasingly common neurodegenerative disorders including Parkinson's disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated alpha S, although a detailed molecular-level mechanism of the action of such species remains elusive. Here, we characterize alpha S aggregation in vitro in the presence of two alpha S-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly accessible C-terminal region of alpha S. Results: We show that both nanobodies inhibit the formation of alpha S fibrils. Furthermore, using single-molecule fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from more stable oligomers to less stable oligomers of alpha S, leading to a dramatic reduction in oligomer-induced cellular toxicity. Conclusions: The results indicate a novel mechanism by which diseases associated with protein aggregation can be inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.
Publisher
BMC
Issue Date
2017-07
Language
English
Article Type
Article
Citation

BMC BIOLOGY, v.15

ISSN
1741-7007
DOI
10.1186/s12915-017-0390-6
URI
http://hdl.handle.net/10203/305029
Appears in Collection
BC-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 55 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0